Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. Richard A. Miller, M.D., president and CEO, and Jeffrey Arcara, chief business officer, will represent the company.

Key points:

• One-on-one meetings with investors scheduled
• Corporate overview presentation on September 10 at 12:00pm ET
• Live webcast available, accessible for 90 days post-event
• Webcast link provided in the investor relations section of Corvus website

This conference participation highlights Corvus Pharmaceuticals' efforts to engage with investors and showcase their latest developments in the biopharmaceutical industry.

News Market Reaction – CRVS

+0.50%

1 alert

+0.50% News Effect

On the day this news was published, CRVS gained 0.50%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26^th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company’s presentation will be on Tuesday, September 10 at 12:00pm ET.

A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

When is Corvus Pharmaceuticals (CRVS) presenting at the H.C. Wainwright Global Investment Conference?

Corvus Pharmaceuticals (CRVS) is presenting on Tuesday, September 10, 2024, at 12:00pm ET during the H.C. Wainwright 26th Annual Global Investment Conference.

Who will represent Corvus Pharmaceuticals (CRVS) at the H.C. Wainwright conference?

Richard A. Miller, M.D., president and CEO, and Jeffrey Arcara, chief business officer, will represent Corvus Pharmaceuticals (CRVS) at the conference.

How long will the webcast of Corvus Pharmaceuticals' (CRVS) presentation be available?

The webcast of Corvus Pharmaceuticals' (CRVS) presentation will be available live and for 90 days following the event.

Where can investors access the webcast of Corvus Pharmaceuticals' (CRVS) presentation?

Investors can access the webcast via the investor relations section of the Corvus Pharmaceuticals (CRVS) website.